MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine to evaluate a number of intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Principal trial goals have been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis patients, whilst one of https://malcolmu009iuf3.dm-blog.com/profile